ESR1 and breast cancer: Recent studies utilizing next-generation sequencing of therapy-resistant and metastatic ERα+ BC have revealed that mutations in the ESR1 gene (ERα) are frequent (30–40%) and contribute to acquired endocrine resistant BC [71–73].